Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several concerns: rising R&D expenses, significant net losses, and execution risks in scaling manufacturing. Although nimacimab shows potential, management's vague responses and strategic risks highlight uncertainties. Despite adequate funding, the financial health appears strained. The market may react negatively due to increased losses and unclear guidance on nimacimab's efficacy, outweighing any optimism from ongoing trials.
Key Financial Performance
Cash and cash equivalents and short-term investments $48.6 million as of June 30, 2025. This is expected to fund operations and key clinical milestones through at least Q1 2027.
Research and development expenses $14.3 million for Q2 2025, compared to $4.1 million for Q2 2024, representing a significant increase due to contract manufacturing, clinical trial costs, discovery, research, and development expenses, and salaries and stock-based compensation expense.
General and administrative expenses $3.9 million for Q2 2025, compared to $4.3 million for Q2 2024, showing a decrease primarily due to reduced general business expenses and legal and professional fees, offset by increases in salaries, stock-based compensation expenses, consulting and advisory fees, and investor relation costs.
Net loss $17.6 million for Q2 2025, including noncash share-based compensation expense of $4.2 million, compared to $7.9 million for Q2 2024, which included noncash share-based compensation expense of $4.3 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nimacimab Phase IIa Study: Enrollment completed ahead of schedule in February. The 26-week extension study is underway with monotherapy and combination arms enrolling. Data Safety Monitoring Committee reviewed the study 4 times with no recommendations for changes. Top-line results expected by late Q3 or early Q4.
Nimacimab Mechanism: Nimacimab is a fully humanized, peripherally restricted CB1 antibody targeting metabolic pathways without central toxicity. It shows negligible brain penetration and uses allosteric noncompetitive inhibition.
Preclinical Data: Nimacimab demonstrated 21.5% vehicle-adjusted weight loss in preclinical studies. It showed durable post-treatment weight loss and reduced rebound weight gain when used after incretin therapy.
Obesity Treatment Market Positioning: Nimacimab is positioned as a next-generation obesity treatment addressing gaps in current incretin-based therapies. It offers potential as a monotherapy, combination partner, and maintenance therapy.
Financial Position: Ended Q2 with $48.6 million in cash and equivalents, funding operations through Q1 2027. R&D expenses increased to $14.3 million due to clinical trial costs and manufacturing.
Team Expansion: Expanded team to 20 employees, including key hires in regulatory affairs, quality, clinical operations, and CMC.
Strategic Focus: Focused on advancing nimacimab through its next development phase, including finalizing Phase IIb protocol and initiating regulatory engagement after top-line data readout.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges that forward-looking statements are subject to risks and uncertainties, including regulatory coordination challenges and potential protocol updates for clinical trials.
Clinical Trial Execution Risks: The success of the Phase IIa and subsequent studies depends on disciplined execution, timely data analysis, and patient enrollment in extension studies. Any delays or issues in these areas could impact timelines and outcomes.
Market Adoption Challenges: Despite the potential of nimacimab, the obesity treatment market is highly competitive, with established GLP-1-based therapies. High discontinuation rates for existing treatments due to side effects like nausea may also pose challenges for adoption.
Financial Risks: The company reported a net loss of $17.6 million for Q2 2025, with significant R&D expenses. While cash reserves are projected to last until Q1 2027, financial sustainability depends on achieving clinical milestones and market success.
Manufacturing and Supply Chain Risks: The company is scaling up manufacturing for Phase IIb studies, which involves risks related to production delays, quality control, and cost management.
Strategic Execution Risks: The company is entering a critical execution period, requiring precise coordination across regulatory, clinical, and operational activities. Any missteps could delay progress and impact strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Phase IIa CBeyond Study: The study is advancing as planned, on budget, and ahead of schedule. Enrollment was completed in February, and the 26-week visit for the last patient is projected to occur shortly. A 26-week extension study is also underway, with approximately 50% of eligible patients expected to participate. Top-line results are expected by late Q3 or early Q4 2025.
Nimacimab Development: Nimacimab is positioned as a next-generation obesity treatment with potential applications as a monotherapy, combination therapy, and maintenance therapy. It is designed to address gaps in the current obesity treatment landscape, including tolerability and durability of weight loss. The company is preparing for Phase IIb studies and expects to finalize the protocol and advance manufacturing and regulatory engagement by Q4 2025.
Financial Guidance: The company has $48.6 million in cash and equivalents, projected to fund operations and key clinical milestones through at least Q1 2027. This includes the completion of the Phase IIa study, Phase IIb manufacturing, and preparatory clinical activities.
Upcoming Milestones: Key events include a KOL event on September 4, 2025, a presentation of Phase I data at EASD on September 19, 2025, and the release of top-line Phase IIa data in late Q3 or early Q4 2025. The company also plans to finalize the Phase IIb protocol and initiate regulatory engagement in Q4 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why was R&D higher in the second quarter, and what progress was made on manufacturing lines?
A:R&D was higher due to approximately $9.1 million spent on contract manufacturing costs, primarily for the Phase IIa resupply for the extension study and the supply for the Phase IIb trial. Progress was made on manufacturing lines, and the company is working with Arecor to develop a higher concentration nimacimab formulation to allow for longer or less frequent dosing.
Q:What is the expected weight loss efficacy for nimacimab at week 26, and what other key metrics are being monitored?
A:The goal is to demonstrate a clinically meaningful weight loss separation from placebo, targeting a placebo-adjusted difference of 5% to 8%. Other key metrics include safety, tolerability, and biomarkers to validate the mechanism and establish a strong safety profile for future dose-ranging studies.
Q:What are the expectations for discontinuation rates within 26 weeks, and how does this compare to GLP-1s in the real-world setting?
A:Discontinuation rates are expected to align with trends in obesity studies, around 25% to 30%. The company sees an opportunity to capture patients who discontinue incretin therapy (50% after one year, 80% after two years) by offering a drug with minimal GI side effects and long-term sustainable weight loss.
Q:What is the enrollment eligibility for the extension study, and why is only 50% of patients from the original study eligible?
A:Patients who complete 26 weeks of dosing are eligible for the extension study. Approximately 50% are eligible due to the extension study being designed after the original study started, leading to some patients completing the study before the extension was set up. Natural early terminations also contributed to the reduced eligibility.
Q:How will CBeyond data guide the development and utility of nimacimab in different modalities (maintenance, monotherapy, combination)?
A:CBeyond data will help identify opportunities in maintenance (targeting patients discontinuing GLP-1 therapy), monotherapy (for patients not responding to GLP-1 therapy), and combination therapy (enhancing weight loss with tolerable doses of incretin therapies). The data will also highlight nimacimab's unique mechanism and safety profile.
Q:What is the protocol for the independent board overseeing the trial for safety, and what types of adverse events are reported?
A:The independent board meets quarterly and reviews all safety data, including adverse events, serious adverse events, and adverse events of special interest (AESIs). They have access to unblinded information and can request clarifications or additional monitoring. Four reviews have been completed with no significant issues reported.
Q:Does the extension study include a follow-up period to track durability of weight loss, and when will data be available?
A:Yes, the extension study includes a 13-week follow-up period to track durability and rebound weight gain. Data from this follow-up period is expected in the first half of 2026.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific expectations for nimacimab's weight loss efficacy at week 26, providing a range (5% to 8%) without committing to a precise target. Additionally, they did not provide precise numbers for the extension study enrollment, citing early stages and logistical challenges.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
DIO mouse
GI
LLC Research
Punit Dhillon
Research Division
TRZ
Today
agent
burden
care
cessation
clarity
combination efficacy
comparison nimacimab
coordination
core
discontinuation
dose tirzepatide
durability weight
efficacy incretin
group weight
improvement glucose
kilogram
line nimacimab
maintenance therapy
metabolic pathway
monotherapy combination
mouse model
nimacimab tirzepatide
obesity treatment
option
progress Phase
rebound
study nimacimab
vehicle weight
weight day
SKYE Transcript
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript
Positive3-10
The earnings call presents a positive outlook with strong clinical development results, particularly in weight loss and body composition improvements. The Q&A highlights robust plans for higher dose studies and formulation advancements, addressing analyst concerns. Despite some management vagueness, the strategic focus on safety, efficacy, and future milestones aligns with market optimism. The combination therapy's success and ongoing R&D efforts suggest potential stock price appreciation.
Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call reveals mixed signals. Financial performance shows increased R&D expenses and a larger net loss, but cash reserves are solid. Product development is promising, with positive feedback on Nimacimab and its potential in obesity treatment. However, uncertainties remain, particularly regarding weight regain issues and the need for higher dosing. The Q&A session highlighted optimism about future trials but also exposed gaps in understanding current data. Overall, the financial health and product prospects balance out, leading to a neutral sentiment.
Skye Bioscience, Inc. (SKYE) CBeyond Phase 2a Clinical Trial Topline Data Conference Call Transcript
Neutral10-6
Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-10
SKYE Slides
SKYE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
